• Mashup Score: 9

    PURPOSE Patients with advanced penile squamous cell carcinoma have a poor prognosis (21% 2-year overall survival [OS] from diagnosis). We assessed the activity of atezolizumab (anti–PD-L1) in patients with advanced penile cancer, with or without radiotherapy (RT). PATIENTS AND METHODS A single-center, nonrandomized phase II study with two treatment arms was conducted in 32 patients with histologically confirmed advanced penile cancer. All patients received atezolizumab (1,200 mg) once every 3 weeks. Twenty patients, who were expected to benefit from RT for locoregional disease control, received additional irradiation. The primary end point was 1-year progression-free survival (PFS) for the complete cohort and was reached if the actual 1-year PFS was at least 35%. Secondary end points included OS, objective response rate (ORR), and tolerability. Exploratory biomarker analyses were conducted in pretreatment specimens. RESULTS Median follow-up was 29.1 months (IQR, 18.1-33.5). Grade 3-4 a

    Tweet Tweets with this article
    • 👍 Durable anti-tumor activity to atezolizumab seen in a subset of patients w/ advanced #PenileCancer ➡️ https://t.co/aIHqikd3yQ #ImmunoOnc #radonc @Hielke_Martijn https://t.co/Q6O6JqDjWK

  • Mashup Score: 1

    Penile squamous cell carcinoma is a rare form of penile cancer with limited treatment options. An international study has found that the use of immune checkpoint inhibitors may offer clinical benefits for some patients with advanced penile squamous cell carcinoma. These findings were published by Talal El Zarif, MD, and colleagues in the Journal of the National Cancer Institute. “These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of

    Tweet Tweets with this article
    • Are Immune Checkpoint Inhibitors Efficacious Among Patients With Penile Squamous Cell Carcinoma? https://t.co/MqQ2R3omBA #immunotherapy #penilecancer #oncology

  • Mashup Score: 0

    In the Dutch single-institution phase II PERICLES trial reported in the Journal of Clinical Oncology, de Vries et al found atezolizumab produced activity in patients with advanced squamous cell carcinoma of the penis. In the study, 32 patients enrolled at The Netherlands Cancer Institute between October 2018 and August 2021 received atezolizumab at 1,200 mg once every 3 weeks for up to 1 year; among these, 20 patients who were expected to benefit from radiotherapy for locoregional control also received a

    Tweet Tweets with this article
    • Atezolizumab With or Without Radiotherapy in Advanced Penile Cancer https://t.co/PDpHZD7DjU #penilecancer #oncology #immunotherapy #radonc

  • Mashup Score: 10

    The European Association of Urology (EAU) Guidelines on Penile Cancer provides up-to-date information on the diagnosis and management of penile squamous cell carcinoma (SCC).

    Tweet Tweets with this article
    • Offer neoadjuvant chemotherapy using a cisplatin- and taxane-based combination to chemotherapy-fit patients w/ pelvic lymph node involvement or those w/ extensive inguinal involvement (cN3) in preference to up front surgery. #EAUguidelines #PenileCancer https://t.co/wyTy9FvaTK

  • Mashup Score: 1

    The European Association of Urology (EAU) Guidelines on Penile Cancer provides up-to-date information on the diagnosis and management of penile squamous cell carcinoma (SCC).

    Tweet Tweets with this article
    • Our newest #EAUUrologyCheatSheets is a collaborative effort with @ASCO to create comprehensive guidelines on #PenileCancer. Review the updated #EAUGuidelines on #PenileCarcinoma with this one page cheat sheet. 🔎 https://t.co/6muA3gZ047 https://t.co/kCZE3LQfK7